INmune Bio starts dosing Alzheimer’s patients in Phase Ib trial
The Phase Ib trial is enrolling patients with mild to moderate Alzheimer’s. Credit: Raman Oza from Pixabay.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more